XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
  Brain Diseases
   Epilepsy
  Demyelinating Diseases
  Headache
  Memory
  Neurochemistry
  Neurodegenerative Diseases
  Regeneration
  Spinal Cord Diseases
  Stroke
  Taste
  Trigeminal Neuralgia
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
Search

Last Updated: Nov 18, 2006 - 1:55:25 PM

Epilepsy Channel
subscribe to Epilepsy newsletter

Latest Research : Neurosciences : Brain Diseases : Epilepsy

   DISCUSS   |   EMAIL   |   PRINT
Propofol is effective in pediatric refractory status epilepticus
Sep 1, 2005 - 8:03:00 AM, Reviewed by: Dr.

�We suggest the use of propofol before thiopental in children with refractory status epilepticus,� said study author J. P. J. van Gestel, MD, of the University Medical Center Utrecht, Wilhelmina Children�s Hospital, in the Netherlands. �Propofol is a fast-acting drug, and little time is lost if it fails to control seizures.�

 
Propofol is a safe and effective drug to treat children with refractory status epilepticus, and it is recommended before thiopental, according to a study in the August 23, 2005 issue of Neurology, the scientific journal of the American Academy of Neurology. Propofol and thiopental are widely used intravenous anesthetics which are also known to help control seizures.

Researchers in the Netherlands examined the effects of propofol and thiopental in 33 children (34 episodes total) with refractory status epilepticus. Refractory status epilepticus is a state in which seizures occur in rapid succession without recovery of consciousness between them. These seizures are resistant to treatment and persist for more than 60 minutes.

Propofol effectively controlled seizures in 14 out of 22 patients. Side effects from propofol were infrequent and minor. Propofol was given at rates lower than 5 mg/kg/h, due to previous reports about potentially fatal side effects when the delivery rate was greater than 5 mg/kg/h. Two patients successfully treated with propofol died, but their deaths were attributed to severe neurological damage after bacterial meningitis.

Twenty patients were treated with thiopental, including the eight in whom propofol was used first without success. Eleven were effectively treated and had seizure control. There were serious side effects during thiopental treatment. Most patients required higher ventilator settings and supplemental oxygen due to suspected pneumonia. The respiratory problems with thiopental treatment were greater than expected, according to the researchers. Eight of the 20 patients died. Two deaths could be attributed to thiopental, but the others were related to the underlying diseases that had caused the refractory seizures.

The average duration of propofol treatment was about 2.4 days, compared to 8.6 days for thiopental treatment.

�We suggest the use of propofol before thiopental in children with refractory status epilepticus,� said study author J. P. J. van Gestel, MD, of the University Medical Center Utrecht, Wilhelmina Children�s Hospital, in the Netherlands. �Propofol is a fast-acting drug, and little time is lost if it fails to control seizures.�

A related editorial in the same issue of Neurology says this study underscores the need for a systematic, prospective study in children and adolescents with this disorder.

�The study by van Gestel et al is retrospective, sequential, and historical in design which prevents definitive conclusions regarding effectiveness,� said editorial authors Nina F. Schor, MD, PhD, a pediatric neurologist at Children�s Hospital of Pittsburgh and James J. Riviello, Jr., MD, of Children�s Hospital, Boston. �Given the devastating nature of refractory status epilepticus, the search for newer and better treatments to control this condition safely and quickly is critically important.�
 

- August 23, 2005 issue of Neurology
 

American Academy of Neurology

 
Subscribe to Epilepsy Newsletter
E-mail Address:

 

The American Academy of Neurology, an association of nearly 19,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer�s disease, epilepsy, Parkinson�s disease, multiple sclerosis, and stroke. For more information about the American Academy of Neurology, visit www.aan.com.

Related Epilepsy News
High frequency oscillation analysis on EEGs offers a new surgical approach to improve seizure control
Anti-epileptic drugs increase risk of fractures in patients above the age of fifty years
More research and attention needed for epilepsy
Recent - onset seizures affect white matter development
Ethosuximide - most effective treatment for childhood absence epilepsy
Studies focusing on early diagnosis and treatment of epilepsy with minimal side-effects
Sudden Unexpected Death In Epilepsy
Topiramate may increase the risk of birth defects
Glutamate- involved in blocking response to anti-epileptic medication
Responsive Neurostimulator System: An implantable device to treat epilepsy


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us